Status:
UNKNOWN
hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Conditions:
Leukemia
Eligibility:
All Genders
Brief Summary
hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation
Detailed Description
Establishment of Clinical Applicable Human Amniotic Epithelial Cell Products and Its Preliminary Application in Allogeneic Hematopoietic Stem Cell Transplantation
Eligibility Criteria
Inclusion
- leukemia patients with allogeneic HSCT
- KFS score \>90
- after transplantation, the patient was implanted (peripheral blood neutrophil absolute value \>500/ul for 3 consecutive days)
- no uncontrolled infection after transplantation
- activity II above aGVHD
- patients agreed to participate in the study
Exclusion
- patients refused to participate in the study
- patients have poor compliance
- has received hormone therapy
- patients had serious heart, lung, liver, kidney and other vital organs damage
- researchers believe that patients who are not suitable for observation study
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03759899
Start Date
July 1 2020
End Date
July 1 2022
Last Update
October 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology
Beijing, Beijing Municipality, China, 100044